uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
Department of Oncology/Pathology, Karolinska Institutet, Cancer Center Karolinska, Stockholm, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm , Ludwig Institute for Cancer Research.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
Show others and affiliations
2006 (English)In: Oncogene, ISSN 0950-9232, Vol. 25, no 35, 4913-4922 p.Article in journal (Refereed) Published
Abstract [en]

High-grade gliomas, including glioblastomas, are malignant brain tumors for which improved treatment is urgently needed. Genetic studies have demonstrated the existence of biologically distinct subsets. Preliminary studies have indicated that platelet-derived growth factor (PDGF) receptor signaling contributes to the growth of some of these tumors. In this study, human high-grade glioma primary cultures were analysed for sensitivity to treatment with the PDGF receptor inhibitor imatinib/Glivec/Gleevec/STI571. Six out of 15 cultures displayed more than 40% growth inhibition after imatinib treatment, whereas seven cultures showed less than 20% growth inhibition. In the sensitive cultures, apoptosis contributed to growth inhibition. Platelet-derived growth factor receptor status correlated with imatinib sensitivity. Supervised analyses of gene expression profiles and real-time PCR analyses identified expression of the chemokine CXCL12/SDF-1 (stromal cell-derived factor 1) as a predictor of imatinib sensitivity. Exogenous addition of CXCL12 to imatinib-insensitive cultures conferred some imatinib sensitivity. Finally, coregulation of CXCL12 and PDGF alpha-receptor was observed in glioblastoma biopsies. We have thus defined the characteristics of a novel imatinib-sensitive subset of glioma cultures, and provided evidence for a functional relationship between imatinib sensitivity and chemokine signaling. These findings will assist in the design and evaluation of clinical trials exploring therapeutic effects of imatinib on malignant brain tumors.

Place, publisher, year, edition, pages
2006. Vol. 25, no 35, 4913-4922 p.
Keyword [en]
PDGF receptor, imatinib, CXCL12, glioblastoma multiforme, microarray
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-81649DOI: 10.1038/sj.onc.1209497ISI: 000239687100009PubMedID: 16547494OAI: oai:DiVA.org:uu-81649DiVA: diva2:109564
Available from: 2007-04-05 Created: 2007-04-05 Last updated: 2012-03-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hesselager, GöranKastemar, MarianneHeldin, Carl-HenrikIsaksson, Anders
By organisation
Department of Genetics and PathologyLudwig Institute for Cancer Research
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 216 hits
ReferencesLink to record
Permanent link

Direct link